West Pharmaceutical Services (WST) Total Non-Current Liabilities (2009 - 2026)

West Pharmaceutical Services (WST) has reported Total Non-Current Liabilities for 18 consecutive years, with $996.3 million the latest figure, recorded in Q2 2026.

• Quarterly Total Non-Current Liabilities rose 4.51% year-over-year to $996.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $996.3 million (up 4.51% YoY) and the FY2025 annual result came in at $1.0 billion, up 13.34% from the prior year.
• Total Non-Current Liabilities retreated to $996.3 million in Q2 2026 per WST's latest filing, from $1.0 billion in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for WST reached as high as $1.0 billion in Q1 2026 and fell as low as $812.1 million in Q3 2022.
• A 5-year average of $906.8 million and a median of $890.8 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities decreased 11.0% — and 2026, when it grew 18.68%.
• Year by year, Total Non-Current Liabilities stood at $880.3 million in 2022, then increased by 1.1% to $890.0 million in 2023, then gained by 1.0% to $898.9 million in 2024, then gained by 13.34% to $1.0 billion in 2025, then dropped by 2.21% to $996.3 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $996.3 million, $1.0 billion, and $1.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.